Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2021-04-25 Report Publication Anno…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
一季报披露提示性公告
Report Publication Announcement Classification · 95% confidence The document is a short announcement (379 characters) indicating that the company's 2021 first quarter report has been approved and is available on a public website. It does not contain the actual financial data or the full report itself, but rather directs investors to where the full report can be found. This fits the pattern of a Report Publication Announcement (RPA) rather than the report itself (such as an Interim/Quarterly Report).
2021-04-25 Chinese
中信证券股份有限公司关于深圳华大基因股份有限公司增加2021年度日常关联交易预计额度的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed verification opinion from CITIC Securities regarding the increase in the 2021 annual expected amount of daily related-party transactions for Shenzhen BGI Genomics Co., Ltd. It includes detailed descriptions of the related-party transactions, their pricing policies, necessity, and approvals by the board, independent directors, and supervisory board. The document is not a financial report but a regulatory compliance and verification statement related to related-party transactions, including legal and procedural compliance. It does not contain financial statements or earnings data but focuses on governance and regulatory compliance aspects of related-party transactions. Therefore, it fits best under Regulatory Filings (RNS) as it is a compliance and verification document that does not fit other specific categories like Annual Report, Interim Report, or Audit Report.
2021-04-25 Chinese
深圳华大基因股份有限公司2020年度非经营性资金占用及其他关联资金往来情况的专项说明
Audit Report / Information Classification · 95% confidence The document is a detailed special explanation regarding non-operating fund occupation and other related party fund transactions for the year 2020 by Shenzhen BGI Genomics Co., Ltd. It includes audited financial data, tables summarizing related party transactions, and is signed by certified public accountants and company officers. The document references an audit report issued on April 22, 2021, and contains substantive financial data and analysis related to related party transactions and fund usage. It is not a full annual report but a standalone audit-related report focusing on specific financial audit findings and related party fund usage. This fits the definition of an Audit Report / Information (AR) filing, which includes standalone audit reports and applied accounting principles, excluding full annual reports. The document length (8602 characters) and content confirm it is not a mere announcement or certification but a substantive audit-related report. FY 2020
2021-04-25 Chinese
关于召开2020年年度股东大会的通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2020 Annual General Meeting (AGM) of Shenzhen BGI Genomics Co., Ltd. It includes information about the meeting date, agenda items, voting procedures, registration details, and attachments such as proxy forms and voting instructions. The document does not contain the actual annual report or financial statements but rather the notification and procedural details for the AGM. The presence of agenda items related to the 2020 annual report and other reports indicates it is an AGM notice. The document length is about 5476 characters, which is consistent with a detailed meeting notice rather than a full annual report. Therefore, the document fits the category of AGM Information (AGM-R).
2021-04-25 Chinese
关于续聘2021年度审计机构的公告
Audit Report / Information Classification · 95% confidence The document is an announcement regarding the reappointment of the audit firm Ernst & Young Hua Ming for the fiscal year 2021. It details the qualifications, independence, and audit fees of the firm, as well as the approval process by the board, audit committee, and supervisory board. It does not contain actual audited financial statements or audit reports but rather discusses the appointment and related procedural matters. The document length is 4448 characters, which is relatively short and consistent with an announcement rather than a full audit report. Therefore, this document is best classified as an Audit Report / Information announcement (AR), as it pertains to audit-related information but is not the audit report itself. FY 2021
2021-04-25 Chinese
关于2020年度利润分配预案的公告
Notice of Dividend Amount Classification · 95% confidence The document is an announcement regarding the 2020 annual profit distribution plan of Shenzhen BGI Genomics Co., Ltd. It details the proposed dividend payout, legal compliance, and approvals by the board, independent directors, and supervisory board. It explicitly states that the plan is subject to approval at the 2020 annual general meeting. The document does not contain full financial statements or comprehensive financial performance data but focuses on the dividend distribution proposal and related approvals. The document length is 2545 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this document is best classified as a Notice of Dividend Amount (DIV), which covers announcements of dividend amounts, payment dates, and related details for shareholders.
2021-04-25 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.